These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31336615)

  • 1. Type 2 Diabetes and Cardiovascular Factors Contrasted with Fibrinolysis Disorders in the Blood of Patients with Peripheral Arterial Disease.
    Wieczór R; Wieczór AM; Kulwas A; Rość D
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31336615
    [No Abstract]   [Full Text] [Related]  

  • 2. Tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in patients with symptomatic lower extremity artery disease.
    Wieczór R; Wieczór AM; Rość D
    Minerva Cardiol Angiol; 2021 Apr; 69(2):161-171. PubMed ID: 32643893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
    Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
    McBane RD; Hardison RM; Sobel BE;
    Am J Cardiol; 2010 Jan; 105(1):17-24. PubMed ID: 20102884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
    Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
    Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral artery disease in type 2 diabetes: the role of fibrinolysis.
    Lapolla A; Piarulli F; Sartore G; Rossetti C; Martano L; Carraro P; De Paoli M; Fedele D
    Thromb Haemost; 2003 Jan; 89(1):91-6. PubMed ID: 12540958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P; Kotuličová D; Staško J; Kubisz P
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolysis defect in long-term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorders.
    Opatrný K; Zemanová P; Mares J; Vít L; Opatrná S; Sefrna F; Hejda V; Tomsů M; Eiselt J; Massry SG
    Am J Nephrol; 2002; 22(5-6):429-36. PubMed ID: 12381940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selected new atherosclerosis risk factors and markers of fibrinolysis in children and adolescents with obesity, hypertension and diabetes].
    Głowińska B; Urban M; Koput A; Galar M
    Przegl Lek; 2003; 60(1):12-7. PubMed ID: 12884639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood.
    Valen G; Eriksson E; Risberg B; Vaage J
    Eur J Cardiothorac Surg; 1994; 8(6):324-30. PubMed ID: 8086178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
    Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
    Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
    Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
    Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.
    DeSouza CA; Jones PP; Seals DR
    Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):362-8. PubMed ID: 9514404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism.
    Chadarevian R; Bruckert E; Leenhardt L; Giral P; Ankri A; Turpin G
    J Clin Endocrinol Metab; 2001 Feb; 86(2):732-7. PubMed ID: 11158038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
    Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
    Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up.
    Rautio A; Boman K; Eriksson JW; Svensson MK
    Diab Vasc Dis Res; 2016 May; 13(3):183-91. PubMed ID: 26818227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus.
    Takada Y; Urano T; Watanabe I; Taminato A; Yoshimi T; Takada A
    Thromb Res; 1993 Sep; 71(5):405-15. PubMed ID: 8236167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.